
|Videos|August 12, 2011
ASCO: Controversies in Phase I Clinical Trials
Author(s)Steve Joffe, MD
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.
Advertisement
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients-phase I trials typically have very low response rates (5% to 10%)-and explain their purpose without exaggerating the likely results.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pembrolizumab/Chemo in Platinum-Resistant GYN Indications
2
Frontline Multiple Myeloma Therapy: Kicking the Can Further Down the Road?
3
FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLC
4
FDA Grants Orphan Drug Designation to Zenocutuzumab in Cholangiocarcinoma
5







































